RNA
NASDAQ · Biotechnology
Avidity Biosciences Inc
$8.34
+0.02 (+0.24%)
Financial Highlights (FY 2026)
Revenue
24.18M
Net Income
-64,276,674
Gross Margin
—
Profit Margin
-265.9%
Rev Growth
+58.4%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 39.7% | 39.7% |
| Operating Margin | -266.6% | -239.9% | -24.8% | -24.2% |
| Profit Margin | -265.9% | -252.6% | -27.6% | -21.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 24.18M | 15.26M | 2.36B | 2.44B |
| Gross Profit | — | — | 936.04M | 969.30M |
| Operating Income | -64,448,316 | -36,609,116 | -583,930,228 | -590,749,120 |
| Net Income | -64,276,674 | -36,511,617 | -651,372,475 | -517,686,100 |
| Gross Margin | — | — | 39.7% | 39.7% |
| Operating Margin | -266.6% | -239.9% | -24.8% | -24.2% |
| Profit Margin | -265.9% | -252.6% | -27.6% | -21.2% |
| Rev Growth | +58.4% | +58.4% | +6.9% | +24.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 2.58B | 3.15B |
| Total Equity | — | — | 5.59B | 5.69B |
| D/E Ratio | — | — | 0.46 | 0.55 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -64,025,559 | -38,389,473 | -865,943,607 | -944,563,645 |
| Free Cash Flow | — | — | -400,975,764 | -475,814,962 |